Speak up with us!
Kidney cancer research is underfunded
40 Lives per day
This year, more than 76,000 Americans will be diagnosed with kidney cancer and almost 14,000 kidney cancer patients will lose their lives. The need for research and additional treatment options is urgent.
A Poor Prognosis
Despite amazing strides in kidney cancer treatment, the prognosis for those with stage IV disease remains poor. The five-year survival rate is just under 10%.
More work needs doing, and we advocate to fund that work.
FUNDING HAPPENS IN D.C.
Every year, lobbyists flood Washington, D.C., to ensure that their interests get prioritized when Congress appropriates funding. In this video, KidneyCAN President Bryan Lewis explains how you have to speak up and get a seat at that table — otherwise, “you’re on the menu.”
A TELLING COMPARISON
Melanoma and kidney cancer have long been considered sister diseases. Both have dire prognoses and a very poor response to traditional chemotherapy and radiation therapy. Both are among the most responsive of all cancers to immunotherapy.
Statistics show 40% more patients die from kidney cancer each year than melanoma. However, in recent years, melanoma research has received in both private funding and federal grants many times the funding for kidney cancer research.
Ready to Fight?
There are so many ways you can help. We need your voice! If every person impacted by kidney cancer did a little to speak up for the community, we would be impossible to ignore.
Join Our Grassroots Army
KidneyCAN is a registered 501(c)(3) nonprofit and does not receive any funding through the Congressionally Directed Medical Research Programs (CDMRP) or KCRP (Kidney Cancer Research Program). Our work is funded by grassroots donors in the kidney cancer community.